Amorepacific Invests in HIER Corp for Beauty-Medical Innovation

Amorepacific Holdings has strategically invested in HIER Corporation, a move designed to forge deeper ties between the beauty and medical aesthetics sectors. This collaboration aims to accelerate the development of innovative solutions that bridge professional dermatological treatments with at-home skincare routines, signaling a significant push into the integrated beauty-medical market.

While the specific investment sum remains undisclosed, the partnership signifies a commitment to leveraging each company's distinct strengths. HIER Corporation, established in 2021, brings its expertise in aesthetic medical device development, bolstered by a robust network of medical professionals and global key opinion leaders. This is complemented by Amorepacific's extensive experience in dermatological science research and advanced skincare technology, positioning the combined entity to address evolving consumer demands for scientifically validated beauty solutions.

The strategic alliance will encompass a broad spectrum of activities, including joint product planning, research and development, and integrated marketing initiatives. Key areas of focus include the creation of next-generation skin boosters, cosmeceuticals, and medical devices. Furthermore, the collaboration intends to develop specialized post-treatment care products and explore synergistic distribution channels within hospital and clinic settings. The companies also plan to jointly research novel raw materials and ingredients, enhancing their product development pipeline.

HIER Corporation has demonstrated a strong growth trajectory, particularly with its flagship product, HILO WAVE, a Dual-HA collagen booster designed for skin regeneration. The company's expansion across markets like Korea, Japan, and Southeast Asia, supported by accumulating clinical evidence, provides a solid foundation for this new venture. This partnership with Amorepacific is expected to amplify HIER Corporation's global reach and R&D capabilities.

Lee Sang-mok, CEO of Amorepacific Holdings, highlighted the ambition to create "next-generation beauty solutions that combine dermatological science and medical device technology," promising novel customer experiences. Echoing this sentiment, Kim In-yong, CEO of HIER Corporation, views the agreement as a pivotal moment for merging HIER's medical aesthetic acumen with Amorepacific's deep research heritage in dermatology. This synergy is anticipated to drive significant advancements in a market increasingly valuing evidence-based efficacy and integrated wellness approaches.

The beauty-medical sector is experiencing robust growth, driven by increasing consumer interest in non-invasive aesthetic procedures and a desire for scientifically backed skincare. This collaboration between HIER Corporation and Amorepacific Holdings is well-timed to capitalize on these trends, potentially setting new benchmarks for product innovation and market penetration in the global beauty-medical arena.